Medscape Conference Coverage, based on selected sessions at the:

American College of Cardiology 56th Annual Scientific Session

March 24 - 27, 2007; New Orleans, Louisiana

This activity is not sanctioned by, nor a part of, the American College of Cardiology.

Featured Coverage

HDL-Targeted Therapies: Still the Best Way Forward?
Statins and Beyond: Good News About Lowering LDL Cholesterol
Lowering Blood Pressure: New Approaches via Renin-Angiotensin System Inhibition
Heart Failure
Drug-Eluting Stents
Acute Coronary Syndromes
Renal Function

Conference News

  • Higher Levels of Inflammatory Marker Associated with Depression in HF

    A new study shows that heart failure patients with higher levels of tumor necrosis factor receptor 1, a marker of inflammation, had an increased risk for depression, up to almost 5-fold for those with levels in the highest quartile. Medscape Medical News, April 11, 2007
  • Calcium Scores in Low-Risk Patients

    New recommendations for CAC scoring suggest the test may meaningfully reclassify "intermediate"-risk patients as high-risk if their scores are >400, but a new analysis from the Dallas Heart Study says this strategy is inefficient and may miss patients in whom a CAC test might lead to important changes in CVD prevention strategies. Heartwire, April 4, 2007
  • ENDEAVOR III at Two Years

    Rates of major adverse cardiac events and target lesion revascularizations at two years were the same for the two drug-eluting stents, although fewer patients randomized to the Endeavor experienced periprocedural non-Q-wave MI, a difference that was maintained over the two years of follow-up. Heartwire, April 4, 2007
  • EXACT/CAPTURE-2: Postmarketing Carotid Stent Registry Data

    Researchers are reporting low rates of death, stroke, and MI and a trend to better outcomes with increased operator experience in FDA-mandated postmarketing data for carotid stent and embolic-protection systems. Medscape Medical News, April 3, 2007
  • UNLOAD Raises Questions About Acute HF Treatment

    Do the clinical effects of volume reduction depend on how it's achieved? A post hoc analysis shows different outcomes even after comparable fluid loss. Heartwire, April 3, 2007
  • Mediterranean and AHA Diets Reduce Events Post-MI

    Both the omega-3-rich Mediterranean diet and the low-fat AHA diet produced impressive reductions in adverse events, as compared with standard care, over 24 months, investigators say. The findings underscore the value of intensively--and repeatedly--offering patients dietary advice. Heartwire, March 30, 2007
  • Nesiritide in Acute HF With Renal Dysfunction

    A small placebo-controlled study finds no evidence that the controversial drug affects renal function in an especially high-risk population. Heartwire, March 30, 2007
  • Hawthorn Extract for Systolic Heart Failure

    But it did show that the commercial preparation, derived from a medicinal plant used widely for centuries, was safe when added to conventional HF medications. The study also hinted that the drug may confer some protection against sudden death. Heartwire, March 28, 2007
  • COURAGE Day Two

    One day after the early release of the COURAGE trial results, debate among doctors about the applicability of the trial findings suggests the study, while putting to rest some important questions, leaves many more unanswered. Heartwire, March 28, 2007
  • STARR: Rosiglitazone Reduces CIMT?

    The thiazolidinedione showed a trend toward reduced carotid IMT, but no effect of ramipril was seen in this substudy of the DREAM trial. These results are consistent with those of the main trial, in which rosiglitazone prevented the development of diabetes but ramipril did not. Heartwire, March 28, 2007
  • ECLIPSE Data Unveiled

    The investigational intravenous antihypertensive clevidipine is as safe as conventional treatments--including nitroglycerin, sodium nitroprusside, and nicardipine--when used in the pre-, peri-, and postoperative period of cardiac surgery, and it might also give superior blood-pressure control, according to new data reported here. Heartwire, March 28, 2007
  • Full Data on AGI-1067

    Full data from the ARISE study were presented this week, and although the study missed its primary end point, investigators say the drug has promise for the reduction of hard cardiovascular events. One expert, however, called the findings neutral and raised questions about certain signals going in the wrong direction. Heartwire, March 27, 2007
  • MERLIN: Mixed Results for Ranolazine

    The trial failed to show any disease-modifying effect in either ACS or stable disease. But the results did provide reassurance that the drug is not proarrhythmic and suggested that it actually has some antiarrhythmic effects. Heartwire, March 27, 2007
  • NOLA: Then and Now

    Returning to New Orleans for the ACC meeting, with the French Quarter looking much the same as ever and the convention center restored, attendees could be forgiven for thinking that nothing much has changed. But doctors who lived through the horror that was Katrina reminded the meeting that life here is far from normal and it will be many years before this is the case. Heartwire, March 27, 2007
  • Torcetrapib Imaging Studies

    The neutral imaging studies provide a flicker of hope for investigators who believe the drug class still might prove to be a beneficial addition to the toolbox of clinicians looking to raise HDL-cholesterol levels. Heartwire, March 27, 2007
  • FUSION-2: Outpatient Nesiritide Infusions Don't Improve Outcomes

    The trial quashes the idea that repeated outpatient nesiritide infusions can help patients with the chronic syndrome and, unexpectedly, casts a vote of confidence in the disease-management model of heart-failure care, according to its investigators. There was no evidence that the drug hurt the kidneys, but the trial may have little to say about the safety of nesiritide when given for its labeled indication, acute decompensated HF. Heartwire, March 27, 2007
  • HDL Mimetic Shows Promise

    Torcetrapib may be dead, but the HDL field is not, with efforts now moving to other methods of increasing this lipoprotein. One such idea, using a new reconstituted HDL product, has shown some promising effects in reducing coronary atherosclerosis, and experts in the field say that further studies of this agent are warranted. Heartwire, March 27, 2007
  • New BP Combo Effective

    The first trial to look at the effect of combining a new direct renin inhibitor, aliskiren, with an angiotensin receptor blocker in a difficult-to-treat hypertensive population finds the two drugs together are more effective at lowering blood pressure than either alone. Heartwire, March 27, 2007
  • ABSORB Trial Results

    First-in-human results with a new bioabsorbable everolimus-eluting stent in the ABSORB trial have prompted expert Dr Patrick Serruys to declare that they may constitute "a new era" in the stent world. But a fault in the stent design means a second-generation device will need to be tested before any firm conclusions can be drawn, he admitted. Heartwire, March 27, 2007
  • DEDICATION: Filter Protection Fails in STEMI

    Yet another distal-protection trial has failed its primary end point, showing no differences in infarct size as measured by ST resolution 30 to 90 minutes postprocedure between a strategy of filter-based distal protection and stenting vs no distal protection in stenting. Heartwire, March 27, 2007
  • Danish Registry, but DES Drop-Off Stabilizes

    DES use has dropped but stabilized in the US, while staying relatively constant elsewhere, even as new registry results from western Denmark point to an increased risk of stent thrombosis and MI after 12 months in DES-treated patients. Experts say there is still more to the story. Heartwire, March 26, 2007
  • SPIRIT III

    The XIENCE V stent, a second-generation everolimus-eluting stent, was significantly better than the Taxus paclitaxel-eluting stent in preventing in-segment late loss. In addition, the XIENCE stent was shown to be noninferior to the Taxus stent in terms of preventing a number of clinically important end points. Heartwire, March 26, 2007
  • Novel Antiplatelet Looks Good

    A phase 2 study in patients undergoing elective PCI has shown encouraging results with a new oral drug that blocks the activation of platelets by thrombin when given on top of aspirin and clopidogrel. Heartwire, March 26, 2007
  • COURAGE: Medical Therapy Bests PCI for Stable CAD

    The two treatment strategies were no different for deaths, MI, stroke, or composite outcomes over a median of 4.6 years, although freedom from angina rates were higher for PCI at earlier time points. Experts stress that PCI still has a role for symptom management in stable CAD, but not for preventing future events. Heartwire, March 26, 2007
  • CRP Predicts Events in CHD

    Levels of CRP are predictive of future risk of cardiovascular events in patients with stable coronary artery disease, and risk starts to increase at lower levels of CRP than previously thought, a new study has shown. Heartwire, March 26, 2007
  • Lowering BP Improves Diastolic Function

    But the trial did not show any additional benefit on diastolic dysfunction of using an antihypertensive therapy based on inhibiting the renin angiotensin system over a regimen using non-RAS inhibitor drugs. Heartwire, March 26, 2007
  • LY518674 Fails to Impress

    Despite being more potent and selective, the novel peroxisome proliferator-activated receptor-alpha agonist failed to deliver in two concomitant studies presented today. The drug also raised safety concerns when it was shown to increase serum creatinine levels. Heartwire, March 26, 2007
  • Rosuvastatin Slows Progression of CIMT in Low-Risk Subjects

    Results of a randomized trial of rosuvastatin in low-risk individuals--those with a Framingham risk score of less than 10%--show that treatment slowed progression of carotid intima-media thickness vs placebo, although it did not cause disease regression. Heartwire, March 26, 2007
  • Negative TWA Test: No ICD

    Difficult-to-manage nonischemic cardiomyopathy patients are now added to the list of people in whom a normal noninvasive microvolt T-wave alternans test will predict a low likelihood of sudden cardiac death. The findings of the ALPHA study show that this simple test can be used to weed out patients who have a good prognosis and are unlikely to benefit from an ICD, said the lead investigator. Heartwire, March 26, 2007
  • EVEREST: Tolvaptan for Acute Heart Failure

    Adding tolvaptan to standard acute therapy helped manage volume overload and relieve dyspnea, but the benefits were small and there were no improvements in long-term clinical outcome. Is the glass half full or half empty? Heartwire, March 26, 2007
Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the American College of Cardiology. These materials and the related activity are not sanctioned by the American College of Cardiology or the commercial supporter of the conference and do not constitute an official part of that conference.